The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)
https://doi.org/10.14412/1996-7012-2025-2-98-101
Abstract
We describe a patient with psoriatic arthritis (PSA) and palmoplantar psoriasis, resistant to standard therapy, who observed a significant decrease in disease activity on the background of upadacitinib at a dose of 15 mg/day. Remission was achieved by the 3rd month of treatment. No adverse phenomena were observed within 6 months of treatment.
About the Author
Yu. A. Lushpaeva
Tumen State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Yulia Arnoldovna Lushpaeva
54, Odesskaya Street, Tumen 625023
References
1. Federal clinical guidelines Psoriatic Arthritis. 2024. https://cr.minzdrav.gov.ru/.
2. Kimak A, Robak E, Makowska J, Wozniacka A. Psoriatic Arthritis: Development, Detection and Prevention: A Scoping Review. J Clin Med. 2023 Jun 5;12(11):3850. doi: 10.3390/jcm12113850.
3. Azuaga A, Ramirez J, Canete J. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int J Mol Sci. 2023 Mar 3;24(5):4901. doi: 10.3390/ijms24054901.
4. Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024 May 15;83(6):706-719. doi: 10.1136/ard-2024-225531.
5. Nash P, Richette P, Gossec L, et al. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022 Aug 3;61(8): 3257-3268. doi: 10.1093/rheumatology/keab905.
6. Mease P, Lertratanakul A, Anderson J, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021 Mar;80(3):312-320. doi: 10.1136/annrheumdis-2020-218870. Epub 2020 Dec 3.
7. Sarabia S, Ranjith B, Koppikar S, Wijerat ne D. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatol. 2022 Sep 27;6(1):71. doi: 10.1186/s41927-022-00287-7.
8. Burmester GR, Stigler J, Rubbert-Roth A, et al. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun; 11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29.
9. Keeling S, Maksymowych W. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Rev Clin Immunol. 2021 Jul;17(7): 701-715. doi: 10.1080/1744666X.2021.1925541. Epub 2021 May 13.
10. Drosos A, Venetsanopoulou A, Voulgari P. Axial Spondyloarthritis: Evolving concepts regarding the disease's diagnosis and treatment. Eur J Intern Med. 2023 Nov:117:21-27. doi: 10.1016/j.ejim.2023.06.026. Epub 2023 Jul 5.
11. Ritchlin C, Colbert R, Gladman D. Psoriatic Arthritis. N Engl J Med. 2017 May 25; 376(21):2097. doi: 10.1056/NEJMx170005.
12. Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019 Sep 20:8:F1000 Faculty Rev-1665. doi: 10.12688/f1000research.19144.1. eCollection 2019.
13. Uppala R, Tsoi L, Harms P, et al. "Auto inflammatory psoriasis"– genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021 Feb;18(2):307-317. doi: 10.1038/s41423-020-0519-3. Epub 2020 Aug 19.
Review
For citations:
Lushpaeva YA. The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation). Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(2):98-101. https://doi.org/10.14412/1996-7012-2025-2-98-101
Views:
717
Email this article 